- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06186414
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC
March 22, 2024 updated by: Jiangsu Simcere Pharmaceutical Co., Ltd.
An Open-Label, Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in Non-Muscle-Invasive Bladder Cancer
This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with Non-Muscle-Invasive Bladder Cancer (NMIBC)
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study starts with a dose escalation part followed by a dose expansion part.
The primary objective of the dose escalation part is to evaluate the safety and tolerability of SIM0237 alone or in combination with BCG, and determine the recommended dose(s) (RD).
The primary objective of the dose expansion part is to evaluate the preliminary efficacy of SIM0237 alone or in combination with BCG.
Study Type
Interventional
Enrollment (Estimated)
108
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tammy Wu, Ph.D
- Phone Number: 13671827233
- Email: wutao@zaiming.com
Study Contact Backup
- Name: Wei Xiong, Master
- Phone Number: 18252091329
- Email: wei.xiong@zaiming.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Not yet recruiting
- Peking University Third Hospital
-
Contact:
- Shudong Zhang, Ph.D
- Email: shootong@163.com
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Not yet recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Zhuowei Liu, Ph.D
- Email: liuzhw@sysucc.org.cn
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Not yet recruiting
- Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
-
Contact:
- Tiejun Yang, Ph.D
- Email: tiejunyang@126.com
-
-
Hunan
-
Changsha, Hunan, China, 410031
- Not yet recruiting
- Hunan Cancer Hospital
-
Contact:
- Shusuan Jiang, Ph.D
- Email: Jiangshusuan@hnca.org.cn
-
-
Shandong
-
Qingdao, Shandong, China, 266071
- Recruiting
- The Affiliated Hospital of Qingdao University
-
Contact:
- Haitao Niu, Ph.D
- Email: niuht0532@126.com
-
Contact:
- Yu Cao, Ph.D
- Email: caoyu1767@126.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 201321
- Enrolling by invitation
- Fudan University Shanghai Cancer Center
-
-
Tianjin
-
Tianjin, Tianjin, China, 300211
- Not yet recruiting
- The Second Hospital of Tianjin Medical University
-
Contact:
- Hailong Hu, Ph.D
- Email: huhailong-yd2y@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Written informed consent.
- ≥ 18 years of age, male or female.
- Histologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1 disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1 disease. Histologic confirmation of urothelial carcinoma (mixed histology tumors allowed if urothelial histology is predominant histology).
- Dose escalation phase: BCG-unresponsive high-risk NMIBC.
- Dose expansion phase: a) Cohorts 1 and 2: BCG-unresponsive CIS (with or without Ta or T1 disease); b) Cohort 3: BCG-unresponsive high-risk Ta or T1 disease.
- Absence of resectable disease after transurethral resection (TURBT) procedures [residual carcinoma in situ (CIS) acceptable]. patients with T1 tumors must undergo repeat resection and biopsy if initial biopsy did not include muscularis propria, to ensure the inclusive of muscularis propria and the absence of invasive tumor.
- Not suitable for or unwilling to undergo radical cystectomy.
- ECOG performance status of 0, 1or 2.
- Life expectancy ≥ 2 years.
- Adequate hematologic and organ function.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. WOCBP and male subjects agree to use adequate contraception.
- Tumor tissue (archival or fresh) for biomarker analysis.
Exclusion Criteria:
- Subjects received TURBT or other surgical treatment for bladder lesions or pelvic radiotherapy within 2 weeks prior to the first dose.
- Previous treatment with: a) Systematic drug administration for the purpose of treating NMIBC. b) Intravesical instillation for the treatment of NMIBC, but intravesical instillation of chemotherapy or BCG therapy beyond 4 weeks prior to the first dose and a single immediate instillation of chemotherapy within 4 weeks prior to the first dose are allowed. c) Intravesical instillation of mucosal protective agents (e.g., sodium hyaluronate) are allowed.
- Subject is participating in an investigational drug or investigational device study.
- Subjects have not recovered from AEs caused by previous anti-tumor treatment.
- History/evidence of prior muscle-invasive, locally advanced, metastatic bladder cancer or upper urinary tract (kidney, renal pelvis, ureter) and prostatic urethral tumors; Patients may be considered for enrollment if they have only upper urinary tract Ta/T1/CIS and have undergone radical nephrectomy more than 2 years prior to the first dose.
- Patients with other malignancies within 5 years before the first dose.
- Any active infection or urinary tract infection requiring systemic treatment by intravenous infusion within 2 weeks before the first dose.
- Subjects with clinically significant cardiovascular disease within 6 months before the first dose of study treatment.
- Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
- Active or chronic hepatitis B or hepatitis C infection.
- Known or suspected active autoimmune diseases.
- Concurrent use of any other anticancer therapy or chronic use of systemic corticosteroids at immunosuppressive doses (more than 10 mg/day prednisone or equivalent).
- History of pneumonitis or interstitial lung disease or severe obstructive pulmonary disease that requires oral or intravenous steroids to help recover.
- Known to be allergic or intolerant to study drugs, monoclonal antibodies, excipients; or allergic or intolerant to BCG (only for subjects receiving combined BCG therapy)
- Subjects discontinued prior BCG treatment due to AEs such as toxemia, systemic infection, or urinary incontinence (only for subjects receiving combined BCG therapy).
- History of allogeneic organ transplantation or graft-versus-host disease.
- Any live vaccines within 4 weeks before the first dose.
- Known mental illness or substance abuse that would interfere with trial complies.
- Subject is pregnant or lactating, or is expected to become pregnant or parent a child during the planned study period.
- Other conditions that investigators consider inappropriate for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation-mono
BCG-unresponsive high-risk NMIBC, receiving SIM0237 monotherapy intravesically.
Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
|
Several dose levels of SIM0237 will be administered as a single agent for evaluation
RD level of SIM0237 will be administered as a single agent for evaluation
|
Experimental: Dose escalation-combo
BCG-unresponsive high-risk NMIBC, receiving SIM0237 and BCG intravesically.
Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
|
Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
|
Experimental: Dose expansion-Cohort 1
BCG-unresponsive CIS, receiving SIM0237 monotherapy intravesically.
Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
|
Several dose levels of SIM0237 will be administered as a single agent for evaluation
RD level of SIM0237 will be administered as a single agent for evaluation
|
Experimental: Dose expansion-Cohort 2
BCG-unresponsive CIS, receiving SIM0237 and BCG intravesically.
Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
|
Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
|
Experimental: Dose expansion-Cohort 3
BCG-unresponsive high-risk Ta or T1, receiving SIM0237 and BCG intravesically.
Induction period (QW for 6 weeks) + a 3-week maintenance course or a 6-week re-induction course at Month 3 + maintenance treatment (QW for 3 weeks) at Months 6, 9, 12, and 18 + optional maintenance treatment at Months 24, 30, and 36.
|
Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose escalation:Dose limited toxicity (DLT)
Time Frame: DLT observation period (up to 21 days)
|
DLT observation period (up to 21 days)
|
|
Dose escalation: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)
Time Frame: through study completion, an average of 5 years
|
Incidence and severity of adverse events (AEs) and serious adverse events(SAEs),and lab abnormalities
|
through study completion, an average of 5 years
|
Dose expansion:Complete response (CR) rate at Month 3
Time Frame: Approximately 3 months
|
Complete response (CR) rate at Month 3 of Cohort 1 and Cohort 2
|
Approximately 3 months
|
Dose escalation: Percentage of participants experiencing AE related dose interruptions and dose delays, dose intensity
Time Frame: through study completion, an average of 5 years
|
Occurrence of AE related dose interruptions, dose delays and dose intensity
|
through study completion, an average of 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 23, 2024
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
December 1, 2030
Study Registration Dates
First Submitted
December 7, 2023
First Submitted That Met QC Criteria
December 29, 2023
First Posted (Actual)
January 2, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
Other Study ID Numbers
- SIM0237-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Muscle-Invasive Bladder Cancer (NMIBC)
-
Prokarium LtdRecruitingA Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBCUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Muscle Invasive Bladder Cancer (NMIBC)United States
-
Ractigen Therapeutics.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)Australia
-
Fidia Farmaceutici s.p.a.TerminatedNon-muscle Invasive Bladder Cancer (NMIBC)Italy
-
Asieris Pharmaceutical Technologies Co., Ltd.CompletedNon-Muscle Invasive Bladder Cancer (NMIBC)United States
-
Anchiano Therapeutics Israel Ltd.TerminatedNon-muscle Invasive Bladder Cancer (NMIBC)United States
-
VitadxFONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTERecruitingNon-muscle Invasive Bladder Cancer (NMIBC)France, Belgium, Spain
-
Aadi Bioscience, Inc.National Cancer Institute (NCI)CompletedNon-muscle Invasive Bladder Cancer (NMIBC)United States
-
University of OxfordMerck Sharp & Dohme LLCTerminatedNon-muscle Invasive Bladder Cancer (NMIBC)United Kingdom
-
Case Comprehensive Cancer CenterWithdrawnNon-muscle Invasive Bladder Cancer (NMIBC) | Bladder Tumor (TURBT)United States
Clinical Trials on SIM0237
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere ZaimingRecruitingLocally Advanced Unresectable or Metastatic Solid TumorUnited States, China